The company will conduct a trial aimed at transplanting OPCs to the site of a spinal cord injury and examining whether it could help restore some function to the patient.
Asterias Biotherapeutics is a biotechnology company focused on the emerging field of regenerative medicine.
More Articles on Spine:
Hospital for Special Surgery Names Dr. Todd Albert Surgeon-in-Chief
Costs for SI Joint Disruption, Sacroiliitis About $270M Over 5 Years
The Robotic Difference: How New Technology Could Impact Spine
